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Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy
Diagnostic Task Force Criteria
Impact of New Task Force Criteria
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Ans C. Wiesfeld, MD, PhD; Paul G.A. Volders, MD, PhD; Irene M. van Langen, MD, PhD;
Douwe E. Atsma, MD, PhD; Dennis Dooijes, PhD; Arjan C. Houweling, MD, PhD;
Peter Loh, MD, PhD; Luc Jordaens, MD, PhD; Yvonne Arens, MD, PhD;
Maarten J. Cramer, MD, PhD; Pieter A. Doevendans, MD, PhD; J. Peter van Tintelen, MD, PhD;
Arthur A.M. Wilde, MD, PhD; Richard N.W. Hauer, MD, PhD
Background—Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy (ARVD/C) Diagnostic Task Force Criteria
(TFC) proposed in 1994 are highly specific but lack sensitivity. A new international task force modified criteria to
improve diagnostic yield. A comparison of diagnosis by 1994 TFC versus newly proposed criteria in 3 patient groups
was conducted.
Methods and Results—In new TFC, scoring by major and minor criteria is maintained. Structural abnormalities are
quantified and TFC highly specific for ARVD/C upgraded to major. Furthermore, new criteria are added: terminal
activation duration of QRS 55 ms, ventricular tachycardia with left bundle-branch block morphology and superior
axis, and genetic criteria. Three groups were studied: (1) 105 patients with proven ARVD/C according to 1994 TFC,
(2) 89 of their family members, and (3) 39 patients with probable ARVD/C (ie, 3 points by 1994 TFC). All were
screened for pathogenic mutations in desmosomal genes. Three ARVD/C patients did not meet the new sharpened
criteria on structural abnormalities and thereby did not fulfill new TFC. In 62 of 105 patients with proven ARVD/C,
mutations were found: 58 in the gene encoding Plakophilin2 (PKP2), 3 in Desmoglein2, 3 in Desmocollin2, and 1 in
Desmoplakin. Three patients had bigenic involvement. Ten additional relatives (11%) fulfilled new TFC: 9 (90%) were
female, and all carried PKP2 mutations. No relatives lost diagnosis by application of new TFC. Of patients with
probable ARVD/C, 25 (64%) fulfilled new TFC: 8 (40%) women and 14 (56%) carrying pathogenic mutations.
Conclusions—In this first study applying new TFC to patients suspected of ARVD/C, 64% of probable ARVD/C patients
and 11% of family members were additionally diagnosed. ECG criteria and pathogenic mutations especially contributed
to new diagnosis. Newly proposed TFC have a major impact in increasing diagnostic yield of ARVD/C. (Circ Arrhythm
Electrophysiol. 2010;3:126-133.)
Key Words: cardiomyopathy  diagnosis  criteria  arrhythmogenic right ventricular dysplasia/cardiomyopathy
 genetics
Arrhythmogenic right ventricular dysplasia/cardiomyopa-thy (ARVD/C) is histopathologically characterized by
fibrofatty replacement, primarily of the right ventricle.1–3 The
gold standard for ARVD/C diagnosis is demonstration of this
alteration of ventricular myocardium, either postmortem or at
surgery. However, to facilitate diagnosis in daily practice, a
task force proposed a set of clinically applicable criteria
(TFC) in 1994, based on ECG, structural, and histological
characteristics of the disease as well as arrhythmias and
family history.4 Abnormalities were subdivided into major
and minor, according to the specificity for ARVD/C. Univer-
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sally, these TFC were adopted as the clinical gold standard to
diagnose patients with ARVD/C. However, because they
were based on characteristics from symptomatic index cases,
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mainly in an advanced stage of the disease, TFC were highly
specific for ARVD/C diagnosis, but lacked sensitivity.
Subsequent clinical research in ARVD/C families and the
discovery of disease-causing mutations, primarily in genes
encoding desmosomal proteins, increased insight in etiology
and pathogenesis of the disease.5–13 Desmosomal impairment
followed by mechanical and electric uncoupling of cardio-
myocytes leads to cell death with fibrofatty replacement.14–19
Resultant activation delay is the essential mechanism for
reentry and thereby ventricular tachycardia (VT).20–23 The
increased clinical and scientific knowledge led to the aware-
ness that changes to diagnostic criteria were a challenge of
highest priority. Therefore, a new task force recently intro-
duced modifications to the 1994 TFC by implementation of
new insights.24 Criteria proven to be highly specific rose from
minor to major and new criteria on activation delay, and VT
morphology as well as genetic criteria were added. Further-
more, quantitative parameters for both imaging modalities
and histopathology were newly introduced and were defined
based on comparison with normal subject data.
The aim of the present study was to compare clinical
diagnosis by new TFC with 1994 criteria, to test the impact
on diagnostic yield. New TFC were applied to the largest
cohort of index patients studied so far, and for the first time
to family members as well.
Methods
Study Population
Newly proposed TFC were applied to 3 different groups of patients.
First of all, we established whether 105 patients with clinically
proven ARVD/C, according to the 1994 TFC, would also fulfill
diagnosis with new TFC. In addition, 89 of their first- and second-
degree family members were analyzed. Finally, 39 patients highly
suspected of ARVD/C were included. These patients scored 3 points
by fulfilling either 1 major and 1 minor or 3 minor criteria of the
1994 TFC and were therefore classified as “probable ARVD/C
patients.”
For inclusion, at least a detailed history and family history,
physical examination, copies of 12-lead ECG recordings, and orig-
inal reports of 2D transthoracic echocardiograms were required.
When performed, outcomes of exercise tests, 24-hour Holter moni-
toring, signal-averaged ECG (SAECG) and electrophysiological
studies (EPS), as well as additional imaging by MRI and/or RV
cineangiography were also included in the analyses. All quantitative
analyses were performed in the different academic medical centers.
The results and reports were collected in the core laboratory in
Utrecht, where final scoring of TFC was performed. Tissue charac-
terizations after biopsies were not taken into account because
histomorphometric tissue analyses or estimations, as defined in new
TFC, had not been performed, and biopsies were all taken from the
interventricular septum instead of the RV free wall.24 ARVD/C
patients who had only been diagnosed after autopsy were excluded.
Seven Dutch University Medical Centers participated in patient
screening. All data were collectively stored and analyzed in the
University Medical Center Utrecht.
New TFC
Compared with the 1994 TFC, modifications are:24 (1) reclassifica-
tion from minor to major of criteria highly specific for ARVD/C:
negative T-waves in V1-V3 and ARVD/C in a first-degree relative,
according to TFC; (2) quantification of RV structural abnormalities
and dysfunction and tissue characterization by RV biopsy; (3) newly
introduced criteria: negative T-waves in V1-V2 or V4-V6; negative
T-waves in V1-V4 with right bundle-branch block (RBBB); terminal
activation duration (TAD) of QRS 55 ms in V1-V3; VT of left
bundle-branch block (LBBB) morphology with superior axis; patho-
genic mutation associated with ARVD/C; and (4) adaptations: late
potentials by SAECG in at least 1 of 3 parameters (was 2 of 3);500
premature ventricular complexes/24 hours on Holter (was 1000).
Both in the 1994 and new TFC, major criteria count as 2 points
and minor criteria as 1 point, with at least 4 points required for
ARVD/C diagnosis.
All ECG parameters were studied in 12-lead ECGs, obtained using
the conventional recording technique at a paper speed of 25 mm/s
with low-pass filter set at 100 Hz. Depolarization and repolarization
parameters were assessed with patients in sinus rhythm, while off
drugs. Epsilon wave was defined as a distinct deflection after the end
of the QRS complex, that is, after the QRS complex had returned to
the isoelectric line.25 TAD was determined as the longest value in
V1-V3, from the nadir of the S wave to the end of all depolarization
deflections.26 VT morphology and axis were considered only when
12-lead ECG recording of the VT was available. VT axis was called
superior when the QRS complex was negative or indeterminate in II,
III, and aVF and positive in aVL, and called inferior in the case of
positive QRS in II, III, and aVF and negative in aVL.
For imaging tests to be scored for new TFC, appropriate quanti-
fications had to be performed.24 During EPS, programmed electric
stimulation was performed according to a previously described
protocol.26 Table 1 shows how many subjects underwent which
additional diagnostic tests.
DNA of all proven and probable ARVD/C index patients was
screened for mutations in genes encoding the desmosomal proteins
plakophilin2 (PKP2), desmoglein2 (DSG2), desmocollin2 (DSC2),
and desmoplakin (DSP), as described earlier.9 Mutations were
considered pathogenic when occurring either in highly conserved
residues or within a (predicted) functionally important domain,
causing changes in charge or predicted major rearrangements of the
protein and when not found in at least 150 ethnically matched control
subjects. In the case a mutation was found in the proband, family
members were only screened for this specific mutation.
The criterion of clinical ARVD/C diagnosis in first-degree rela-
tives was only counted in nonindex patients.
Statistical Analysis
Continuous variables are expressed as mean1 SD. Discrete vari-
ables are shown as percentages. Continuous variables were com-
pared with use of the Student t test. Categorical variables were
analyzed by use of contingency tables and the Pearson 2 method.
In the case that the expected value was 5, the Fisher exact test
was used instead. In the case of repeated measurements, the
Wilcoxon signed-rank test was used for continuous data and
McNemar test for nominal data. A value P0.05 was considered
statistically significant. SPSS 15.0 software (SPSS, Chicago, Ill)
was used for calculations.
Table 1. Additional Examinations Performed in the 3 Groups
Patients With
Proven
ARVD/C
(n105)
n (%)
Family Members
(n89)
n (%)
Patients With
Probable
ARVD/C
(n39)
n (%)
24-Hour Holter monitoring* 105 (100) 55 (62) 38 (97)
Exercise test 81 (77) 46 (52) 30 (77)
Late potentials
SAECG 35 (33) 15 (17) 6 (15)
Mapping during EPS 19 (18) 1 (1) 4 (10)
EPS 82 (78) 11 (12) 18 (46)
MRI 64 (61) 26 (29) 33 (85)
RV cineangiography 45 (43) 3 (3) 10 (11)
*Either ambulatory or during admission.
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Results
The cohort comprised 125 patients with proven ARVD/C
index, diagnosed according to the 1994 TFC. Twenty patients
were excluded from this study: 7 were diagnosed only after
autopsy, and of 13 no appropriate quantitative analyses of
imaging tests were available. The 105 index patients who
were included had a mean age at diagnosis of 3913 years,
with a mean duration of follow-up of 108 years. The 89
family members underwent first cardiological screening at
age 3918 years and were followed for 53 years on
average. Finally, the 39 patients with probable ARVD/C were
followed for 109 years after the first evaluation at age
3811 years.
Table 2 shows prevalence of new TFC measured in the 3
different groups.
Patients With Proven ARVD/C
These 105 patients had first presented with VT with LBBB
morphology (n86), ventricular fibrillation (VF, n9), fre-
quent premature ventricular complexes (PVC, n8), or be-
cause of sudden death of a family member (n2). In total, 55
patients carried 21 different PKP2 mutations, whereas 3
patients had a DSG2 and 1 a DSC2 mutation. Furthermore,
3 patients had mutations in 2 genes: 2 in PKP2 plus DSC2 and
1 in PKP2 plus DSP.
ECG abnormalities during sinus rhythm were the most
prevalent abnormalities. As many as 103 of 105 patients did
fulfill at least 1 of the criteria on depolarization and/or
repolarization. The 1994 TFC of negative T waves in V1-V3
was already fulfilled by 70 patients (67%). However, 8
additional patients had T-wave inversions only in V1-V2 and
3 patients with a RBBB had negative T waves in V1-V4 and
thereby fulfilled newly introduced criteria.
Structural abnormalities, both major and minor, were
observed in 83 probands, in 24 cases only by MRI (n15)
and/or RV cineangiography (n12).
With 1994 TFC, major structural abnormalities were ob-
served in 79 patients. According to the new quantified
definitions, 14 were categorized as minor and 3 as not
abnormal. Because of this decrease, 3 patients scored only 3
points in new TFC and were thereby reclassified as “proba-
ble” patients. Two patients had akinetic areas with only mild
dilation of the RV and 1 had RV dyskinesia only.
In 9 of 82 patients who underwent EPS, this produced VT
with LBBB morphology and superior axis, which had not
been recorded spontaneously.
Results of the scoring according to 1994 versus new TFC,
for all 3 patient groups, are conveyed in the Figure.
Family Members
Of the 89 relatives from 40 different families, 77 (87%)
underwent cardiological evaluation because of family screen-
ing. The remaining 12 initially presented because of VT,
syncope. or palpitations (4 individuals each). In total, 59
relatives carried 13 different pathogenic mutations in PKP2
and 1 in DSG2.
Clinically, disease manifestation was mainly by ECG changes
during sinus rhythm. In total, 39 family members met at least 1
of those criteria, with fulfillment of criteria both on depolariza-
tion and repolarization in 9 cases. Structural abnormalities were
observed in 23 individuals, in 1 case only with MRI and in 1
case by RV cineangiography (Table 2). VTs with LBBB
morphology were induced in 3 of 11 family members who
underwent EPS, twice with inferior and once with superior axis.
Table 2. Prevalence of New Diagnostic TFC in the 3 Groups
Patients With
Proven
ARVD/C
(n105)
Family Members
(n89)
Patients With
Probable
ARVD/C
(n39)
Age, y 4812 4417 4812
Male, n (%) 81 (77) 34 (38) 21 (54)
Diagnosis according to
1994 TFC, n (%) 105 (100) 22 (25) 0
New TFC, n (%) 102 (97) 32 (36) 25 (64)
New TFC, n (%)
Depolarization
abnormalities
78 (74) 28 (31) 19 (49)
Epsilon wave V1-V3* 11 (10) 3 (3) 0
QRS 110 ms* 23 (22) 1 (1) 0
Late potentials‡ 29 (54) 5 (31) 5 (50)
Prolonged TAD 56 (53) 25 (28) 16 (41)
Repolarization
abnormalities
81 (77) 20 (22) 21 (54)
Inverted T waves
V1-V3*†
70 (67) 15 (17) 17 (44)
Inverted T waves
V1-V2
8 (8) 5 (6) 4 (10)
Inverted T waves
V4-V6
0 0 0
Inverted T waves
V1-V4RBBB
3 (3) 0 0
Arrhythmias 99 (94) 24 (27) 36 (92)
LBBB VT with
superior axis*
45 (43) 2 (2) 14 (36)
LBBB
VTinferior/unknown
axis
94 (90) 11 (12) 33 (85)
500 PVCs on 24-h
Holter‡
25 (24) 17 (31) 9 (24)
Structural alterations 83 (79) 23 (25) 22 (56)
Major 62 (59) 12 (13) 13 (33)
Minor 21 (20) 11 (12) 9 (23)
Family history
Clinically confirmed
ARVD/C in
first-degree
relative*†
NA 74 (83) NA
Pathologically
confirmed ARVD/C in
first-degree relative*
6 (6) 13 (15) 0
Pathogenic mutation* 62 (59) 59 (66) 16 (41)
Sudden death 35 y 9 (9) 3 (3) 5 (13)
*Major criterion.
†Minor in 1994 TFC, upgraded to major in new TFC.
‡In percentage of subjects measured.
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According to the 1994 TFC, 22 (25%) members of 17
families had been diagnosed with ARVD/C. All carried
pathogenic PKP2 mutations. These 22 (mean age, 4517
years, 8 men) all kept diagnosis when new TFC were applied.
In addition, 10 more members of 9 families fulfilled
ARVD/C diagnosis with new TFC (1 man and 9 women,
including 2 twin sisters). In 1994 TFC, 7 had scored 3 points,
all by different combinations of criteria, and 3 only had a
positive family history. All 10 carried a pathogenic PKP2
mutation. Additional TFC points were scored by ECG
changes: prolonged TAD, T-wave inversion in V1-V3 or
V1-V2 (n4, 3 and 2, respectively). None of the newly
diagnosed relatives revealed VT with LBBB morphology and
superior axis or between 500 and 1000 PVCs on 24-hour
Holter monitoring.
Of 55 female relatives, 23 (42%) fulfilled new TFC for
ARVD/C diagnosis, whereas 9 of 34 (26%) men were
diagnosed. Both sex groups had similar age and percentage of
mutation carriers. Difference of fulfilled criteria between
individuals with and without ARVD/C diagnosis is conveyed
in Table 3. In 32 of 59 (54%) relatives carrying a pathogenic
mutation, ARVD/C was diagnosed. Of all 57 family members
without diagnosis, 27 (47%) fulfilled at least 1 criterion, in
addition to the positive family history, in another category.
They all carried a pathogenic mutation (26 in PKP2, 1 in
DSG2) (Table 3).
Figure. Changes in score and diagnosis when applying 1994
and new TFC in the 3 groups.
Table 3. Prevalence of TFC in Individuals With Versus Without Diagnosis According to New TFC
Diagnosis According to New TFC, n (%)
Family Members
(n89)
Patients With
Probable ARVD/C
(n39)
Yes No Yes No
Age, y 32 (36) 57 (64) 25 (64) 14 (36)
Male, n (%) 4415 4418 4910 4615
New TFC, n (%) 9 (28) 25 (44) 15 (60) 6 (43)
Depolarization abnormalities
Epsilon wave V1-V3* 3 (9) 0 0 0
QRS 110 ms* 1 (3) 0 0 0
Late potentials‡ 3 (60) 2 (25) 3 (43) 2 (67)
Prolonged TAD 15 (47) 10 (18) 10 (40) 6 (43)
Repolarization abnormalities
Inverted T waves V1-V3*† 15 (47) 0 15 (60) 2 (14)
Inverted T waves V1-V2 4 (13) 1 (2) 2 (8) 2 (14)
Inverted T waves V4-V6 0 0 0 0
Inverted T waves V1-V4RBBB 0 0 0 0
Arrhythmias
LBBB VT with superior axis* 2 (6) 0 13 (52) 1 (7)
LBBB VTinferior/unknown axis 9 (28) 2 (4) 23 (92) 10 (71)
500 PVCs on 24-h Holter‡ 17 (65) 0 4 (17) 5 (36)
Structural alterations
Major 12 (38) 0 12 (48) 1 (7)
Minor 10 (31) 1 (2) 6 (24) 3 (21)
Family history
Clinically confirmed ARVD/C in first-degree relative*† 28 (88) 46 (81) NA NA
Pathologically confirmed ARVD/C in first-degree relative* 6 (19) 7 (12) 0 0
Pathogenic mutation* 32 (100) 27 (47) 14 (56) 2 (14)
Sudden death 35 y 1 (3) 2 (4) 1 (4) 4 (29)
*Major criterion.
†Minor in 1994 TFC, upgraded to major in new TFC.
‡In percentage of subjects measured.
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Patients With Probable ARVD/C
The large majority of these patients highly suspected of
ARVD/C initially presented with monomorphic VT with
LBBB morphology (n29, 74%). Four men had VF as a first
symptom at mean age 22 years (range, 21 to 25). The
remaining 6 patients’ first symptoms were palpitations due to
frequent PVCs (n5) and syncope. Overall, age at first
symptoms, current age, and sex were similar to proven
ARVD/C patients. In total, 14 patients carried a pathogenic
mutation in PKP2. Furthermore, 2 patients carried 2 patho-
genic mutations each: 1 in PKP2 and DSG2 and the other in
DSC2 and DSG2.
In 10 of 35 patients who underwent MRI and/or RV
cineangiography, structural abnormalities were thereby newly
discovered. VT with LBBB morphology and superior axis
was recorded only after induction by programmed electric
stimulation in 7 of 18 patients who underwent EPS.
When applying new TFC, 25 (64%) patients were diag-
nosed with ARVD/C. Pathogenic mutations were found in 14
of these 25, all in PKP2. Thus, 14 of 16 (88%) patients with
pathogenic mutations fulfilled new TFC. In 6 patients, car-
rying a mutation was essential for diagnosis. Besides muta-
tions, diagnosis was mainly due to additional points newly
scored by prolonged TAD, negative T waves in V1-V3, and
VT with LBBB morphology and superior axis (Table 2).
Eleven patients could have been diagnosed based on ECG
parameters only.
On the contrary, fewer points were scored on structural
abnormalities. Whereas initially major and minor structural
abnormalities were observed in 20 and 8 patients, respec-
tively, this was only 13 and 9, respectively, according to new
definitions. Age and sex were not related to new diagnosis.
When all 3 groups studied are taken into account, a higher
percentage of individuals with spontaneous VT and/or VF
fulfilled new TFC than 1994 TFC (see Table 4; P0.001 for
all individuals together, P0.001 and P0.500 for probands
and family members, respectively).
Discussion
In this study, we assessed the effect of newly proposed Task
Force criteria on ARVD/C diagnosis. Application of new
TFC additionally diagnosed ARVD/C in 35 individuals: 10 of
89 (11%) relatives and 25 of 39 (64%) previously classified
as probable index patients. On the contrary, 3 of 105
ARVD/C patients previously classified as “proven” did not
fulfill new TFC.
The gold standard for ARVD/C diagnosis is demonstration
of transmural fibrofatty replacement in the RV at autopsy or
after surgery. Of all patients included in this study, autopsy
has been performed in 2 of 3 proven ARVD/C patients who
died after diagnosis. Of the 7 ARVD/C patients diagnosed by
autopsy, excluded from this study, no clinical cardiological
data were available. Because new TFC could not be com-
pared with the gold standard, it cannot be established what
percentage of ARVD/C patients is truly identified by the new
TFC. However, previous research results provided at least 3
arguments to support diagnostic superiority of new TFC to
1994 TFC.
Improvement of Diagnosis
First of all, basic and genetic studies performed during the
past decade provided insight into the pathophysiological
mechanism of ARVD/C.5–19 The pathognomonic RV fibro-
fatty replacement appears to be preceded by mutation-related
desmosomal changes and associated gap junction remodeling.
This is strongly supported by a recent study of Asimaki et
al.27 They showed that specifically in ARVD/C, altered
localization of desmosomal and gap junction proteins occur
in ventricular areas (still) without evidence of fibrofatty
modifications. Resultant electric uncoupling and, at a later
stage, the surviving myocardial bundles embedded in the
fibrofatty infiltration forming communicating zigzag courses,
all lead to lengthened conduction pathways and conduction
slowing due to load mismatch.14,15 These delays in activation
are crucial in providing a substrate for reentry and thereby
VT.20,21,28 The 1994 TFC comprised 3 criteria on activation
delay: epsilon waves, QRS prolongation, and late potentials.
In our previous studies, confirmed by Marcus et al, we
demonstrated that prolonged terminal activation duration in
V1-V3 is an indicator of RV activation delay more sensitive
than epsilon waves and QRS prolongation and still highly
specific for ARVD/C.26,29,30
Second, electric activation mapping and CARTO electro-
anatomic voltage mapping provided advanced insight in the
sites of the RV that were electrically affected.28,31 These
techniques demonstrated that loss of vital myocardium of
inferior parts of the RV can result in reentry-based VTs with
a LBBB morphology and superior axis. On the contrary,
idiopathic VT from the RV outflow tract results in VT with
nonsuperior axis. Therefore, recording of a LBBB VT with
superior axis appeared to be more specific for ARVD/C.
Third, in contrast to 1994 TFC, normal values for new TFC
were based on comparisons to large numbers of healthy
control subjects. Establishment of optimal cutoff points was
performed scientifically by analyses of ROC curves.24
Application of New TFC
In all 3 groups studied, patients lost points previously scored
on structural abnormalities. Reasons for that are 2-fold. First,
observation of either a-/dyskinetic area or major dilatation of
the RV was sufficient to fulfill a major criterion in 1994.
However, according to new TFC definitions, both a-/dyski-
nesia and RV dilatation are required for echocardiography
Table 4. Diagnosis in Individuals With Spontaneous VT and/or VF
VT/VF
Recorded
n (%)*
Diagnosis in Patients With VT/VF
According to
1994 TFC New TFC
Yes No Yes No
Proven ARVD/C
patients
97 (89) 97 0. 94 3
Family members 13 (15) 9 4 11 2
Probable ARVD/C
patients
37 (95) 0 37 25 12
Total 106 41 130 17
*Percentage of total number in the specific patient group.
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and MRI. Second, clear cutoff values for degrees of dilation
are newly introduced to avoid subjective interpretations. Still,
overlap between healthy and diseased cannot be excluded
entirely. Especially in endurance athletes, physiological RV
dilatation and deformation occur, which may mimic
ARVD/C.32
Multiple studies on different cohorts demonstrated that
ECG changes are the earliest and most sensitive indicators of
ARVD/C.5–7,30 This was acknowledged by the members of
the new international task force. The contribution of ECG
abnormalities, both with respect to depolarization and repo-
larization as well as arrhythmias, was increased importantly
in new TFC. ARVD/C could already have been diagnosed in
62 (61%) proven, 11 (44%) probable ARVD/C patients, and
7 (22%) family members if only these ECG parameters would
have been taken into account.
In the present study, prolonged TAD, as activation delay
parameter, was observed in ARVD/C patients with similar
frequency as late potentials. In 22 proven ARVD/C patients,
3 family members and 3 probable ARVD/C patients without
a prolonged TAD, RV activation delay was observed as QRS
110 ms and/or late potentials. We speculate that this
difference might be due to the fact that prolonged TAD is
only measured in leads V1-V3. Because these leads face the
RV outflow tract, activation delay in other parts of the RV is
not detected. Further studies are needed to evaluate the
applicability of prolonged TAD in all ECG leads to establish
whether this criterion may be used as the sole criterion for
depolarization abnormalities.
Despite ECG changes being considered the earliest and
most sensitive abnormalities seen in ARVD/C, in this study,
prevalence of ECG criteria in sinus rhythm was similar
between probable ARVD/C patients with and without diag-
nosis according to new TFC.5–7,30 However, all 14 nondiag-
nosed patients are clearly affected by some kind of disease.
Longer follow-up will have to show whether they are in an
early stage of ARVD/C or another kind of cardiomyopathy.
Thereby, follow-up can also inform us about the TFC
specificity.
The criterion of negative T waves in leads V4-V6 was
introduced because of the awareness of a left-dominant form
of the disease.33 These patients have fibrofatty alterations
primarily in the left ventricle. None of the proven ARVD/C
patients fulfilled this criterion, suggesting that either the
left-dominant form was indeed not acknowledged by the
1994 TFC or that this form is a rare entity. However, in
ARVD/C, desmosomal and gap junctional remodeling occur
in both ventricles and the interventricular septum, also in the
absence of fibrofatty alterations.27 Why histological alter-
ations are primarily found in the RV free wall is not yet
completely understood. It is speculated this is related to
increased wall stress affecting the thin RV free wall more
than other structures.7
Identification of pathogenic mutations is newly included as
diagnostic criterion. DNA analysis revealed mutations in the
PKP2 gene in 131 patients. This is in accordance with
previous Dutch ARVD/C studies.9,34 Due to founder muta-
tions, PKP2 appears to be the main genetic factor causing
ARVD/C. Mutations in DSG2, DSC2, and DSP were found in
6, 4, and 1 of 233 subjects studied, respectively. For 6
probable ARVD/C patients and 2 second-degree family
members, having a pathogenic mutation was crucial for
ARVD/C diagnosis according to the new criteria.
The total group of ARVD/C probands diagnosed with new
TFC contains more men than women (n95 versus 32). This
is in accordance with previous clinical studies, which re-
ported male:female ratios of approximately 3:1.8–10 On the
contrary, among family members included in this study, more
women were diagnosed. All criteria occurred in similar
frequencies in both sex groups. Negative T waves in V1-V3
and mutations were observed more frequently in women than
in men (in 41% versus 24% and 72% versus 59%, respec-
tively), but the differences were not significant. These find-
ings are in agreement with previous studies, in which no
unequivocal conclusions on sex differences could be
drawn.35,36 However, these studies pointed out that although
equally affected, male ARVD/C patients and/or mutation
carriers are more often symptomatic than their female coun-
terparts. Therefore, men are more likely to be the first in a
family to be diagnosed and thereby become the proband.
Although debate on true sensitivity of the clinical diagnos-
tic criteria for ARVD/C will continue, especially in case of
asymptomatic relatives, multiple studies from various coun-
tries worldwide have repeatedly confirmed certain parameters
to be highly specific for ARVD/C. The consensus reached by
a group of experts in the field from all over the world
translates state-of-the-art knowledge on ARVD/C into a set of
criteria useful in daily clinical practice.24 Modifications made
on the 1994 TFC have provided an important increase in
diagnosing ARVD/C. Further studies will have to prove the
true value of the new TFC.
Study Limitations
This study was hampered by the fact that not all diagnostic
modalities had been performed in all patients, particularly
with respect to RV imaging and late potential detection. In
addition to 2D echocardiography, the majority of index
patients underwent MRI and/or RV cineangiography. How-
ever, this was only performed in 31% of family members;
thus, structural and functional abnormalities might have been
missed. Similarly, 82 (78%) proven and 18 (46%) probable
ARVD/C patients but only 11 (12%) family members under-
went EPS. Furthermore, late potentials were measured in only
80 of 233 individuals included in this study because SAECGs
are not performed in all participating hospitals and late
potential mapping was rarely carried out during EPS. Holter
monitoring was performed significantly more often in family
members ultimately with diagnosis according to new TFC
(81% versus 51%), due to already existing suspicion of
abnormalities. Application of these diagnostic modalities in
more subjects probably will increase the number of criteria
fulfilled and thereby the number of patients diagnosed with
ARVD/C.
Results of biopsies were not included in this study. How-
ever, biopsies had been taken from none of the family
members and only from 1 probable ARVD/C patient, who
already fulfills new TFC without biopsy taken into account.
Therefore, the number of patients diagnosed in these 2 groups
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would not have been influenced by inclusion of biopsy
results.
Conclusion
This is the first large study comparing ARVD/C diagnostic
criteria from 1994 with the newly proposed TFC.4,24 Newly
proposed TFC increase ARVD/C diagnosis importantly, es-
pecially due to modifications on ECG and genetic criteria.
This will result in ameliorated identification of affected
individuals and thereby contribute to prevention of both
ventricular tachyarrhythmias and sudden death.
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CLINICAL PERSPECTIVE
Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is characterized by progressive loss of predomi-
nantly RV myocardium, which is replaced by fibrofatty tissue. Typically, affected individuals present with ventricular
tachycardia between the 2nd and 4th decades of life, but ARVD/C can also cause sudden death in adolescence. Clinical
diagnosis is made according to generally accepted task force criteria (TFC). This initial set of criteria, dating from 1994,
was highly specific but lacked sensitivity. Therefore, a modified set of TFC was recently proposed. In new TFC, scoring
by major and minor criteria is maintained. Structural abnormalities are quantified and TFC highly specific for ARVD/C
are upgraded to major. Furthermore, new criteria are added: terminal activation duration of QRS 55 ms, ventricular
tachycardia with left bundle-branch block morphology and superior axis, and genetic criteria. In the present study, we
applied new TFC to 3 groups: (1) 105 patients with proven ARVD/C according to 1994 TFC, (2) 89 of their family
members, and (3) 39 patients with probable ARVD/C (ie, 3 points by 1994 TFC). In total, 35 individuals were newly
diagnosed with ARVD/C: 10 of 89 (11%) relatives and 25 of 39 (64%) previously classified as probable index patients.
On the contrary, 3 of 105 ARVD/C patients previously classified as “proven” did not fulfill new TFC. ECG criteria and
pathogenic mutations especially contributed to new diagnosis. Therefore, newly proposed TFC have a major impact in
increasing diagnostic yield of ARVD/C.
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